BioSpace News Archive

Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the closing of its previously announced initial public offering of 2,500,000 American depositary shares (“ADSs”), each representing three Class A ordinary shares at a public offering price of US$23.00 per ADS.

Neural Therapeutics Inc. (“Neural” or the “Company”) is pleased to announce the formal appointment of Dr. Jason Dyck, Dr. Kelly Narine and Colin McLelland to the Company’s board of directors.

Kiora Pharmaceuticals (NASDAQ: KPRX) has received Investigational New Drug Application approval in Australia to enroll up to six additional patients in the ABACUS study of KIO-301

OCYONBIO, a contract development and manufacturing organization focused on advanced therapies, announced a strategic agreement with Marchesini Group, a leading global provider of sterile filling and packaging solutions for pharmaceutical and Biotech companies.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2023 before the market opens on Wednesday, October 25, 2023, and will hold a conference call on the same day at 8:30 a.m. EDT.

Two analyses have shed light on an important factor when evaluating treatments that significantly reduce bodyweight: their effect on muscle composition.

Yield10 Bioscience, Inc. announced that the harvest of a majority of the winter and spring Camelina sativa grain produced under grower contracts in 2022/2023 has been completed.

Kashiv Biosciences LLC today announced that they have entered into an exclusive licensing agreement for ADL018 (also called AVT23), a proposed biosimilar to Xolair® (omalizumab), which is in clinical development.

BioCentriq, a cell therapy CDMO, announced the appointment of Jennifer Manning, MPA, as its Chief Commercial Officer, effective October 3, 2023.

Scilex Holding Company provides notice to all record holders and beneficial owners of restricted shares of Scilex common stock that were part of the previously announced dividend of Scilex common stock then-held by Sorrento Therapeutics, Inc. to Sorrento equity holders of record as of January 9, 2023.